This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
by Zacks Equity Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
BJRI, CARA, BOOM, STNG, and UL have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2021.
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
by Zacks Equity Research
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 24.19% and -80.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara (CARA) Surges 14%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.
Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.
Palatin (PTN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.
Are Options Traders Betting on a Big Move in Cara Therapeutics (CARA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri
by Zacks Equity Research
Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.
Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA
by Zacks Equity Research
Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.
XOMA Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
by Zacks Equity Research
Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.